Results 81 to 90 of about 98,661 (266)

Prolonged fenfluramine use in open‐label studies of Dravet or Lennox–Gastaut syndromes: Long‐term safety, tolerability, patient global functioning, and considerations for interpreting effectiveness

Epilepsia, EarlyView.
This graphical abstract provides an overview of the content from this open‐label extension study of fenfluramine use in patients with Dravet syndrome or Lennox‐Gastaut syndrome. Abstract Objective Long‐term safety and global functioning are reported in patients with Dravet syndrome (DS) or Lennox–Gastaut syndrome (LGS) treated with fenfluramine in an ...
Antonio Gil‐Nagel, Kelly G. Knupp, Boudewijn Gunning, Domenica Immacolata Battaglia, Elizabeth A. Thiele, Ingrid E. Scheffer, An‐Sofie Schoonjans, Rima Nabbout, Nathalie Villeneuve, Kerstin Alexandra Klotz, Nicola Specchio, Rocio Sanchez‐Carpintero, Marta Zolnowska, Anne‐Liv Schulz, Lily Perrin, Najla Dickson, Mélanie Langlois, Amélie Lothe, Joseph Sullivan   +18 more
wiley   +1 more source

Evaluation of Changes in Heart Rate Variability Associated with Puppy Growth Using Phase-Rectified Signal Averaging (PRSA) and Non-Gaussianity Index

Animals
Heart rate variability (HRV) reflects autonomic nervous system (ANS) activity through nonlinear mechanisms, including complex beat-to-beat fluctuations and chaos-like dynamics of healthy cardiac rhythms.
Rio Hayashi, Mizuki Hasegawa, Akari Hatanaka, Ahmed S. Mandour, Miki Hirose, Kazumi Shimada, Lina Hamabe, Ken Takahashi, Ryou Tanaka   +8 more
doaj   +1 more source

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Mavacamten is the first and only cardiac myosin inhibitor approved in 5 continents for the treatment of adults with symptomatic New York Heart Association class II and III obstructive hypertrophic cardiomyopathy.
Anjali T. Owens, Milind Desai, Matthew T. Wheeler, Anna Rodonski, Samira Merali, Amy J. Sehnert, Sara Saberi   +6 more
doaj   +1 more source

Longest survivor of pulmonary atresia with ventricular septal defect without surgical intervention

ESC Heart Failure, Volume 12, Issue 2, Page 1499-1507, April 2025.
Sang Zhou, Yu Wu, Guoran Li, Yongwen Qin, Man Qi, Zhitao Jin   +5 more
wiley   +1 more source

Asymptomatic Cardiotoxicity After High‐Dose Anthracycline Treatment in Sarcoma Patients Assessed by Biomarkers and Echocardiography

International Journal of Cancer, EarlyView.
ABSTRACT Treatment of sarcoma includes high‐dose anthracyclines, which can cause cardiotoxicity. This study assesses the correlation of cardiac biomarkers and echocardiographic parameters on asymptomatic cardiotoxicity in sarcoma patients treated with anthracyclines.
Elissa A. S. Polomski, Frank M. Speetjens, J. Wouter Jukema, Julius C. Heemelaar, Michiel A. J. van de Sande, Hans Gelderblom, M. Louisa Antoni   +6 more
wiley   +1 more source

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang, Chunlan Deng, Xiaogang Guo, Hui Yan   +3 more
wiley   +1 more source

Maternal and perinatal outcomes of pregnant women with echocardiographically high probability of pulmonary arterial hypertension

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective This study aimed to describe maternal and perinatal outcomes among pregnant women with echocardiographically high probability of pulmonary arterial hypertension (PAH) managed at a quaternary center and to compare outcomes between women with and without cardiac complications (CC).
Laura Belmont‐Rojo, Rosa Hernandez‐Cruz, Ana Jimena Lopez‐Diaz, Diana Yazmin Copado‐Mendoza, Tirso Rubalcava‐Rubalcava, Mario Isaac Lumbreras‐Marquez, Maria Antonia Pijuan‐Domenech   +6 more
wiley   +1 more source

Percutaneous Thrombectomy Using AngioJet in Acute Pulmonary Embolism With Clot in Transit

Respirology Case Reports
Percutaneous pulmonary thrombectomy using the AngioJet device is a feasible option for the management of acute pulmonary embolism with a clot in transit in selected high‐risk patients. Further large‐scale studies are needed to better establish the safety
Atif Saleem Siddiqui
doaj   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai, Hirohiko Aikawa, Yoshiaki Morita, Keiko Ohta‐Ogo, Teruo Noguchi   +4 more
wiley   +1 more source

Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI

iNew Medicine, EarlyView.
Advancing HF Screening: Integrating Technology and Risk Factors Across Eras. This diagram provides a comprehensive review of the historical developments and projected trends of heart failure (HF) screening methodologies, with the prevalent risk factors for HF depicted at the base.
Xiaofeng Fang, Yinbo Xu, Yiting Zhao, Liuyi Li, Zhengyi Cheng, Zhongqi Zhang, Yuhang Luo, Qiaoling Liu, Chen Gong, Shichun Shen   +9 more
wiley   +1 more source